Research Stage Programs

Our drug delivery platform is broadly applicable to small molecules, peptides, and proteins. PharmaIN expects to identify and characterize 6-7 new molecules for internal development and/or joint development (license) over the next 18 months.

Our goal is to add 2-3 small molecules, natural sequence peptides, and proteins each to our available list of products for further development. For example, we have successfully formulated a cousin of GLP-1, the peptide GLP-2 (for potential use in numerous gastrointestinal disease settings).

Our focus is on highly active molecules, particularly peptides - a new, untapped resource for novel, high impact therapeutics. Pipeline candidates are expected to target unmet medical needs where our delivery technology can make significant clinical impact. Highly competitive markets, such as generic or biogeneric or high sales/marketing spend markets, will be prime opportunities for partnering. Current IP and partnership activity limits specific disclosure of targets, however, disease markets include cancer, growth factors, pain management, inflammation, metabolic, and infectious disease. Small molecules, peptides, and large market off-patent proteins have been slotted for evaluation and screening.

For interested investors, the company will enter into signed Confidentiality Agreements necessary to discuss specific product pipeline molecules. A list of potential collaborative projects can be found here.